AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9742977
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of metformin in sulphonylurea-treated patients (n=268)
Trial: 9742977
Drug: Combined analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined analysis of metformin-allocated patients
Trial: 2929979
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg sublingual nifedipine after weaning from bypass
Trial: 27965306
Drug: Intralesional (IL)
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional (IL) injection
Trial: 27965306
Drug: Intranodal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranodal (IN) injection
Trial: 27965306
Drug: Both intralesional
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intralesional and intranodal (ILN) injection
Trial: 16418872
Drug: Rowatinex 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rowatinex 200 mg t.i.d.
Trial: 12945875
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg enoxaparin once daily
Trial: 10580782
Drug: Current users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current users of lipid-lowering medications
Trial: 10580782
Drug: Past users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Past users of lipid-lowering medications
Trial: 10580782
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-users of lipid-lowering medications)
Trial: 8656503
Drug: Lamivudine-zidovudine combination
RxNorm normalized name: lamivudine / zidovudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine-zidovudine combination therapy (300 mg lamivudine every 12 hours + 200 mg zidovudine every 8 hours for 24 weeks)
Trial: 8656503
Drug: Zidovudine monotherapy
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine monotherapy for 24 weeks
Trial: 7010528
Drug: Carbenoxolone sodium
RxNorm normalized name: carbenoxolone sodium
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone sodium (Biogastrone tablets) 100 mg three times a day for 4 weeks, continued for another 4 weeks if ulcers were not healed
Trial: 7010528
Drug: Dummy tablets
RxNorm normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy tablets (control group)
Trial: 7010528
Drug: Amiloride 5
RxNorm normalized name: amiloride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 5 mg three times a day
Trial: 25779222
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - three sessions in 3 months
Trial: 25098969
Drug: Discontinued medications
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued medications
Trial: 19749003
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF-DPI) 400 microg (1 x 400 microg/inhalation; treatment B)
Trial: 19749003
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF-DPI) 400 microg (2 x 200 microg/inhalation; treatment A)
Trial: 19749003
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two inhalations; treatment C)
Trial: 7607973
Drug: Adjuvant therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapies (ECP and doxorubicin/cyclophosphamide)
Trial: 3138056
Drug: Prazepham (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazepham (20 mg)
Trial: 31377075
Drug: GC3114 (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC3114 (high-dose, quadrivalent influenza vaccine)
Trial: 31377075
Drug: Control (standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard-dose quadrivalent influenza vaccine)
Trial: 26994300
Drug: Calcitonin gene-related
RxNorm normalized name: Calcitonin gene-related peptide
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin gene-related peptide infusion (1.5 µg/min)
Trial: 26321502
Drug: Standard-dose epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose epirubicin and cyclophosphamide (SDE) (8 × 60 mg/m(2))
Trial: 26321502
Drug: Higher-dose epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose epirubicin and cyclophosphamide (HDE) (8 × 100 mg/m(2))
Trial: 12117043
Drug: Theophylline (Theo-Dur
RxNorm normalized name: THEOPHYLLINE (THEO-DUR) 300MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (Theo-Dur 300 mg bd)
Trial: 9570170
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg 3 times a day plus Omeprazole 40 mg daily for 14 days followed by 20 mg daily for 14 days (Group 1)
Trial: 9570170
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily for 28 days (Group 2)
Trial: 9570170
Drug: Ranitidine hydrochloride
RxNorm normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine hydrochloride 150 mg twice a day for 28 days (Group 3)
Trial: 16961011
Drug: Interpretive play
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interpretive play therapy
Trial: 30268262
Drug: Kefir group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kefir group (2 × 100 ml of kefir per day)
Trial: 30268262
Drug: Toothpaste group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste group (toothpaste with probiotic content, brushed twice a day)
Trial: 24473502
Drug: Amiodarone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone plus ranolazine (1500 mg single oral dose)
Trial: 11281469
Drug: Normal menstrual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal menstrual blood loss (<60 mL)
Trial: 9690973
Drug: Sertindole (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole (24 mg)
Trial: 26957279
Drug: Hemoperfusion combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoperfusion combined therapy (HD+HP)
Trial: 26434090
Drug: Anterolateral joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterolateral joint line injection site
Trial: 26434090
Drug: Suprapatellar lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprapatellar lateral injection site
Trial: 21173687
Drug: Metenolone enanthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metenolone enanthate (ME) 100 mg injected intramuscularly weekly for 6 weeks
Trial: 18313521
Drug: Multicatheter interstitial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicatheter interstitial brachytherapy (n=247) or MammoSite (n=26), receiving 32-34 Gy in 8-10 twice-daily fractions using high-dose-rate 192Ir brachytherapy.
Trial: 10579155
Drug: New paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New paste preparation of Gelfoam powder, Thrombostat, acetic acid, and Bacitracin ointment
Trial: 10579155
Drug: Old method
RxNorm normalized name: Oldenlandia diffusa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old method using small pieces of Gelfoam soaked in antibiotic solution
Trial: 8723582
Drug: Perioperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative treatment with epoetin alfa
Trial: 8723582
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of epoetin alfa and preoperative ABD
Trial: 7037511
Drug: Highly purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified porcine insulin (after removing patients with substantial changes in HbA1)
Trial: 7037511
Drug: Highly purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified porcine insulin (after removing patients with low initial insulin binding capacity)
Trial: 7037511
Drug: Bovine insulin
RxNorm normalized name: Bovine insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine insulin (after rechallenge)
Trial: 26934504
Drug: Post-operative concurrent
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative concurrent radiochemotherapy (p-RTCT)
Trial: 24687640
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg nicotine patch applied during the night
Trial: 21708892
Drug: Dilute rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilute rice vinegar (100 ml daily for 4 weeks)
Trial: 21708892
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (100 ml of water)
Trial: 14967827
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of caffeine per day for 5 days
Trial: 7586105
Drug: Midazolam infusion
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam infusion (0.3-0.5 mg.min-1)
Trial: 2239119
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (bolus) followed by 0.25% (infusion)
Trial: 2239119
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% (bolus) followed by 0.125% (infusion)
Trial: 24637559
Drug: High-dose sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sildenafil
Trial: 20479228
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group with newly trained lexical categories for color (e.g., different shades of blue acquiring new names)
Trial: 18191684
Drug: Daily spontaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily spontaneous awakening trials (SATs) followed by spontaneous breathing trials (SBTs)
Trial: 18191684
Drug: Sedation per
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation per usual care plus a daily SBT
Trial: 15625071
Drug: Mupirocin cream
RxNorm normalized name: Mupirocin Cream
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin cream
Trial: 3093773
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous dextrose infusion
Trial: 3093773
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous amino acid infusion
Trial: 31712981
Drug: Conventional‐F toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional‐F toothpaste (1,450 μg F/g)
Trial: 31712981
Drug: Conventional‐F +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional‐F + arginine/CaCO3 (1,450 μg F/g + 1.5% arginine‐CaCO3)
Trial: 31712981
Drug: High‐F toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐F toothpaste (5,000 μg F/g)
Trial: 31712981
Drug: High‐F +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐F + fTCP toothpaste (5,000 μg F/g)
Trial: 15910557
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (ATV)
Trial: 26892128
Drug: Ezetimibe/Simvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Simvastatin + Atorvastatin (E/S + ATV)
Trial: 30231121
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard pharmacological treatment)
Trial: 23276524
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (combined treatment)
Trial: 4044462
Drug: Latamoxef (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latamoxef (1 g)
Trial: 4044462
Drug: Cephazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephazolin (1 g) and Metronidazole (500 mg)
Trial: 30664407
Drug: Functional-Analytic Psychotherapy
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional-Analytic Psychotherapy and Acceptance and Commitment Therapy (FACT)
Trial: 27216710
Drug: Sources of
RxNorm normalized name: Dental Resources brand of Stannous Fluoride Dental Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sources of information about HPV vaccine (e.g., doctor or medical professional, television)
Trial: 27216710
Drug: Parental attitudes
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental attitudes about HPV vaccine
Trial: 27216710
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine uptake
Trial: 16283812
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of intrusive force to the maxillary incisors
Trial: 16283812
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g of intrusive force to the maxillary incisors
Trial: 11011336
Drug: Bisoprolol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg
Trial: 29783863
Drug: Erenumab 140
RxNorm normalized name: Erenumab 140 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 140 mg and subcutaneous sumatriptan 12 mg
Trial: 29783863
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo and subcutaneous sumatriptan 12 mg
Trial: 21975206
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg MBP8298, given by IV injection once every 6 months for 2 years
Trial: 21975206
Drug: Placebo, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given by IV injection once every 6 months for 2 years
Trial: 18297821
Drug: Yiqigushen Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqigushen Capsule combined with levofloxacin
Trial: 18297821
Drug: Yiqigushen Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqigushen Capsule only
Trial: 11213741
Drug: Antibiotic irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic irrigation through canaliculi
Trial: 11213741
Drug: Antibiotic irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic irrigation with isolated microorganisms
Trial: 11213741
Drug: Antibiotic irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic irrigation with no isolated microorganisms
Trial: 9310603
Drug: Modest salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modest salt restriction (5 g salt intake)
Trial: 9310603
Drug: Normal salt
RxNorm normalized name: SODIUM CHLORIDE 1 g ORAL TABLET [Normal Salt]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal salt intake (10 g salt intake)
Trial: 7870975
Drug: Lithium/haloperidol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium/haloperidol treatment
Trial: 30041929
Drug: Dalantercept, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalantercept, administered subcutaneously at 1.2 mg/kg every 3 weeks until disease progression or unacceptable toxicity
Trial: 27597278
Drug: Thoracic irradiation
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic irradiation with concomitant weekly paclitaxel (experimental arm)
Trial: 27597278
Drug: Thoracic irradiation
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic irradiation without concurrent chemotherapy (control arm)
Trial: 25243839
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol 3350‐electrolyte solution (PEG), 4‐L dose
Trial: 23522096
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose of levothyroxine (target range 4.1 to 8.0 mU/L)
Trial: 23522096
Drug: Standard levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard levothyroxine replacement (target range 0.4 to 4.0 mU/L)
Trial: 20609969
Drug: Exenatide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (2 mg, once-a-week injection)
Trial: 20609969
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (once-daily injection, starting dose 10 IU)
Trial: 18835539
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acids 8 g/day (EAA group; n=21)
Trial: 18835539
Drug: No supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplements (controls; n=17)
Trial: 14669420
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (LDA, 75 mg daily)
Trial: 14669420
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (20 g daily)
Trial: 14669420
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid and low molecular weight heparin simultaneously
Trial: 14669420
Drug: Isolated occurrence
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated occurrence of lupus anticoagulant antibodies
Trial: 14669420
Drug: Occurrence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occurrence of anticardiolipin antibodies
Trial: 14669420
Drug: Anticardiolipin antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticardiolipin antibodies with lupus anticoagulant antibodies simultaneously
Trial: 7987976
Drug: ADR-529 (600-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADR-529 (600-1000 mg/m2) with epirubicin (60-100 mg/m2), cyclophosphamide (600 mg/m2), 5-fluorouracil (600 mg/m2), and tamoxifen (30 mg)
Trial: 7987976
Drug: Epirubicin (60-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (60-100 mg/m2)
Trial: 7987976
Drug: ADR-529 (600-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADR-529 (600-1000 mg/m2)
Trial: 3166194
Drug: 0.1% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% NaF solution, applied nine times
Trial: 27540904
Drug: Mannitol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 0.25 g/kg (Group A)
Trial: 27540904
Drug: Mannitol 0.5
RxNorm normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 0.5 g/kg (Group B)
Trial: 27540904
Drug: Mannitol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 1.0 g/kg (Group C)
Trial: 27540904
Drug: Mannitol 1.5
RxNorm normalized name: CYCLOPHOSPHAMIDE 2GM/MANNITOL 1.5GM/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 1.5 g/kg (Group D)
Trial: 24247662
Drug: Incentives offered
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incentives offered (antiviral medication, vaccine, double pay, free room and board)
Trial: 21364273
Drug: Alfacalcidol 1
RxNorm normalized name: alfacalcidol 1 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 1 μg daily + Alendronate 70 mg weekly + 500 mg calcium daily
Trial: 21364273
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Alendronate 70 mg weekly + 500 mg calcium daily
Trial: 15494330
Drug: Active extracorporeal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active extracorporeal shock wave therapy (2000 pulses, energy flux density 0.03-0.17 mJ/mm(2))
Trial: 15494330
Drug: Sham extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham extracorporeal shock wave therapy
Trial: 15494330
Drug: Active extracorporeal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active extracorporeal shock wave therapy